Table 1.
Patients’ characteristics for each randomized group
| 11C-CHOLINE PET (n = 16 patients) n (%) | 68Ga-PSMA PET (n = 18 patients) n (%) | 18F-FACBC PET (n = 15 patients) n (%) | |
|---|---|---|---|
| General characteristics | |||
| Median age at PET1, years | 76 | 76 | 78 |
| Median PSA at PET1, ng/ml | 11.3 | 19.4 | 17.8 |
| Median first PSA on ARTA, ng/ml | 26.1 | 7.8 | 8.0 |
| Previous docetaxel | 3 (18.8%) | 2 (11.1%) | 0 |
| Bisphosphonates use | 5 (31.3%) | 4 (22.2%) | 2 (13.3%) |
| Biochemical response (reduction of PSA >50% from baseline) | 6 (33.3%) | 4 (22.2%) | 5 (33.3%) |
| Biochemical progression (increase of PSA >50% from baseline) | 6 (33.3%) | 2 (11.1%) | 7 (46.7%) |
| EORTC response at PET2 | 0 CR, 2 PR, 4 SD | 1 CR, 3 PR, 4 SD | 0 CR, 3 PR, 1 SD |
| EORTC progression at PET2 | 9 PD | 7 PD | 7 PD |
| Median bPFS, months | 5 | 2 | 6 |
| PET-derived parameters | |||
| Median major SUVmax at PET1 | 9.20 | 30.65 | 11.2 |
| Median major SUVmax at PET2 | 11.50 | 30.40 | 11 |
| Median total MTV at PET1 | 162.10 | 56 | 278.2 |
| Median total MTV at PET2 | 216.55 | 75.5 | 109.7 |
| Median total TLA at PET1 | 467.45 | 515.8 | 969.1 |
| Median total TLA at PET2 | 789.80 | 1403.4 | 470.1 |
| Patients not undergoing PET2 | 1 (6.3%) | 3 (16.7%) | 4 (26.7%) |
| Sites with PET uptake at PET1 | |||
| Prostate | 9 (56.3%) | 5 (27.8%) | 6 (40%) |
| Pelvic lymph nodes | 7 (43.8%) | 7 (38.9%) | 2 (13.3%) |
| Extra-pelvic lymph nodes | 11 (68.8%) | 10 (55.6%) | 3 (20%) |
| Bone | 12 (75%) | 12 (66.7%) | 10 (66.7%) |
| Lung | 1 (6.3%) | 4 (22.0%) | 2 (13.3%) |
| Liver | 0 | 0 | 0 |
| Abdominal nodules | 0 | 0 | 0 |
ARTA, androgen receptor-targeting agents; bPFS, biochemical progression-free survival; CR, complete response; EORTC, European Organisation for Research and Treatment of Cancer; MTV, metabolic tumor volume; PD, progression disease; PET, positron emission tomography; PR, partial response; PSA, prostate-specific antigen; SD, stable disease; SUVmax, maximum standard uptake value; TLA, total lesion activity.